Request Deal Involvement

URUS completed the acquisition of Trans Ova Genetics from Precigen for $180m.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Davis Polk & Wardwell

legal advisors

Davis Polk & Wardwell

Rabobank

financial advisors

Rabobank

Finn Partners

pr advisors

Finn Partners

Morgan Lewis & Bockius

legal advisors

Morgan Lewis & Bockius

or

Principals

TRANS OVA GENETICS

target

TRANS OVA GENETICS

PRECIGEN

vendor

PRECIGEN

URUS

bidder

URUS

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - URUS completed the acquisition of Trans Ova Genetics from Precigen for $180m.